Scynexis Inc (SCYX) Stock Price, Quote & News

Company Profile

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to t...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 201 884 5485

Website: www.scynexis.com

Address:

1 Evertrust Plaza, 13th Floor, Jersey City, United States

OfficialStocktwitsUser Feb. 12 at 9:21 PM

$SCYX RSI: 44.37, MACD: 0.0289 Vol: 0.06, MA20: 0.74, MA50: 0.68 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ImadogImaMut Feb. 12 at 1:19 PM

$SCYX I do not believe we will make it to the Mar 10 pre market earnings 🍀 What would they say ? We have been driven down by tax loss selling at the end of 2025 primarily by Federated waiting “too long for too long “ and now that we have secured deals in China and our drug is being re manufactured and supplied in Canada and the US There is no actual announcements about relaunch . So sc178 which is a great drug well GSK does not what to even mention it 🫨😆As a CEO I have tried to be firm and fair I. Our dealings with GSK. It’s like trying to negotiate with your superior and they want you to believe we are in this together and the work you do is something nobody wants. We just have more cash than I know what to do with so I do t know what these guys want but it’s OK I will keep moving us forward even though I can’t tell you shareholders what is actually goi g on behind the scenes ( post is what I would say were I David ) 😎🤔🍀

1 · Reply

pantarei Feb. 11 at 7:45 AM

$SCYX here’s clearly something structured going on behind the scenes...

0 · Reply

DataJim Feb. 10 at 11:49 PM

$SCYX Just noticed that we have three straight earning beats and that we are forecasting a profit for a fourth quarter. Is that from the $20 million settlement or are we expecting to actually see royalty start flowing?

1 · Reply

XZeroDelta Feb. 10 at 8:53 PM

$SCYX appears today there was rotation into the biotech sector. Looks like people bought Scynexis today and either initiated new positions or dollar cost averaged. Been holding this company since 2022. This stock is very undervalued and is under the radar of few investors when compared to other companies. I plan to keep on holding until Scyx-247 comes into market in the distant future.

0 · Reply

DataJim Feb. 10 at 8:07 PM

$SCYX With today’s rally Scynexis passed $OBDC as my top holding.

0 · Reply

LemuelPitkin Feb. 10 at 5:48 PM

$SCYX if you buy, and you plan to hold, the pump and dump will be painless and irrelevant.

0 · Reply

Slashtank Feb. 10 at 5:45 PM

$SCYX about to blow up, buy with both hands

0 · Reply

Valueisoutthere Feb. 10 at 5:32 PM

$SCYX still bullish, and patient

0 · Reply

Zaga64 Feb. 10 at 1:31 PM

$SCYX I have been accumulating shares for the past five weeks. There is a good balance sheet and low cash burn. There is potential for revenue flow and a possible buyout. The current price appears undervalued. I own CHRS at $0.92 and ZNTL at $1.32, and currently SCXY is at an average of $0.72. GLTA.

0 · Reply

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Nov 19, 2025, 7:00 AM EST - 3 months ago

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK

Nov 5, 2025, 4:20 PM EST - 3 months ago

SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 15, 2025, 8:00 AM EDT - 4 months ago

SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study

Sep 4, 2025, 8:30 AM EDT - 5 months ago

SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Aug 13, 2025, 4:30 PM EDT - 6 months ago

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

May 28, 2025, 8:30 AM EDT - 9 months ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

Mar 12, 2025, 5:08 PM EDT - 1 year ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Nov 6, 2024, 4:30 PM EST - 1 year ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 10, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 3, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Aug 27, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 23, 2024, 7:00 AM EDT - 1 year ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

May 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 30, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Apr 9, 2024, 4:05 PM EDT - 2 years ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 2, 2024, 10:04 AM EDT - 2 years ago

Scynexis: Update Following Restructuring Of GSK Deal

Mar 28, 2024, 4:01 PM EDT - 2 years ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Jan 29, 2024, 5:15 PM EST - 2 years ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Jan 8, 2024, 4:00 AM EST - 2 years ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 5, 2024, 8:30 AM EST - 2 years ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Jan 4, 2024, 7:00 AM EST - 2 years ago

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 29, 2023, 4:00 AM EST - 2 years ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

Dec 28, 2023, 9:00 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

Dec 22, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 21, 2023, 8:00 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 19, 2023, 5:30 AM EST - 2 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 18, 2023, 6:46 PM EST - 2 years ago

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'

Dec 18, 2023, 6:15 AM EST - 2 years ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 13, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 8, 2023, 5:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 6, 2023, 7:00 AM EST - 2 years ago

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 4, 2023, 7:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 1, 2023, 6:00 AM EST - 2 years ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 30, 2023, 8:30 AM EST - 2 years ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

Nov 29, 2023, 7:50 PM EST - 2 years ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 22, 2023, 11:45 PM EST - 2 years ago

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 21, 2023, 7:00 AM EST - 2 years ago

IMPORTANT JANUARY DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 19, 2023, 11:45 PM EST - 2 years ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 17, 2023, 11:15 AM EST - 2 years ago

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

OfficialStocktwitsUser Feb. 12 at 9:21 PM

0 · Reply

ImadogImaMut Feb. 12 at 1:19 PM

1 · Reply

pantarei Feb. 11 at 7:45 AM

$SCYX here’s clearly something structured going on behind the scenes...

0 · Reply

DataJim Feb. 10 at 11:49 PM

1 · Reply

XZeroDelta Feb. 10 at 8:53 PM

0 · Reply

DataJim Feb. 10 at 8:07 PM

$SCYX With today’s rally Scynexis passed $OBDC as my top holding.

0 · Reply

LemuelPitkin Feb. 10 at 5:48 PM

$SCYX if you buy, and you plan to hold, the pump and dump will be painless and irrelevant.

0 · Reply

Slashtank Feb. 10 at 5:45 PM

$SCYX about to blow up, buy with both hands

0 · Reply

Valueisoutthere Feb. 10 at 5:32 PM

$SCYX still bullish, and patient

0 · Reply

Zaga64 Feb. 10 at 1:31 PM

0 · Reply

Zaga64 Feb. 10 at 1:21 PM

$SCYX https://finance.yahoo.com/news/invasive-fungal-infections-market-witness-223100962.html

1 · Reply

ImadogImaMut Feb. 10 at 11:49 AM

$SCYX Standing bid at .7731 so far 100 vol 🍀

0 · Reply

ImadogImaMut Feb. 10 at 11:25 AM

$SCYX Wondering if cheapskates GSK will ever mention meetings with FDA with regards yo Brex 178 the besting fooking antifugal available in the world for YEAST infections it’s been kept under taps for several years ( needlessly ) I wonder how many women have suffered in silence perhaps have relationships destroyed or serious mental health issues because the some well meaning older Physician from butfk nowhere is not up to date with the small biotech world has a big secret 🤫 GSK ! 📣 You have an obligation to bring this to market double step ! 😎 please 🙏

0 · Reply

GordonRamen Feb. 9 at 2:51 PM

$SCYX Antifungal biotech; niche market with established generic competition.

1 · Reply

SS_67 Feb. 9 at 2:48 PM

$SCYX https://www.msn.com/en-gb/health/other/candida-auris-the-killer-fungus-spreading-across-the-globe/ss-AA1TBdGD?ocid=winp2fptaskbarent&cvid=cba57526a2a04f44e1c83917f0f153cb&ei=20#interstitial=9

0 · Reply

pjinvestmentco Feb. 9 at 1:38 PM

$SCYX I don't believe there was 1 mention of Brexafemme in the GSK earnings report and slides...plenty of everything else Loser...

0 · Reply

Aagshsg Feb. 7 at 9:02 PM

$SCYX how high do u think this can go guys? Can we get it back to $2? Or will GSK buy them out first

1 · Reply

ImadogImaMut Feb. 6 at 1:49 PM

$SCYX Bought 200 at 8:33 and at 8.47 still no change on ST ?

1 · Reply

SnapCrackleStop Feb. 5 at 2:53 PM

$SCYX look at the historical trading on this. @ The 20th of each month since Nov it trades 2mm shares in an up trend. The big boys are accumulating… So am I. $$$

1 · Reply

jonhie Feb. 4 at 2:20 PM

$SCYX Nice buy 30k at 0,79

0 · Reply

ImadogImaMut Feb. 4 at 1:01 PM

$SCYX avg fill .7467 even though I offered to pay .78 ( the offer )

1 · Reply

ImadogImaMut Feb. 4 at 12:59 PM

$SCYX I’m taking the offer at .78 for a few hundred in 1 minute live lol 🙏🎯🙌

1 · Reply

Market Cap	34.04M
Revenue (ttm)	3.75M
Net Income (ttm)	-21.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	0.73
Profit Margin	-567.73%
Debt to Equity Ratio	0.00

Volume	316,700
Avg Vol	427,254
Day's Range	N/A - N/A
Shares Out	41.97M
Stochastic %K	74%
Beta	1.35
Analysts	Strong Sell
Price Target	$3.67